Literature DB >> 12870124

Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.

Shawn A Hill1, Patricia A Lloyd, Shannon McDonald, Jennifer Wykoff, David Derse.   

Abstract

A single-cycle infection assay with recombinant viral vectors was developed to study human T cell leukemia virus type I (HTLV-I) replication and its inhibition by antiviral agents. The susceptibility of HTLV-I to 6 nucleoside reverse-transcriptase inhibitors was examined. HTLV-I replication was inhibited by tenofovir, abacavir, lamivudine, zalcitabine, stavudine, and zidovudine.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12870124     DOI： 10.1086/376531

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  Adult T cell leukemia lymphoma.

Authors:  Lee Ratner
Journal:  Front Biosci       Date:  2004-09-01

2.  De novo human T-cell leukemia virus type 1 infection of human lymphocytes in NOD-SCID, common gamma-chain knockout mice.

Authors:  Paola Miyazato; Jun-ichirou Yasunaga; Yuko Taniguchi; Yoshio Koyanagi; Hiroaki Mitsuya; Masao Matsuoka
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  Inhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1.

Authors:  Risaku Fukumoto; Miroslav Dundr; Christophe Nicot; Anthony Adams; Valerio W Valeri; Lawrence E Samelson; Genoveffa Franchini
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

4.  Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α.

Authors:  Beatrice Macchi; Emanuela Balestrieri; Caterina Frezza; Sandro Grelli; Elena Valletta; Ambroise Marçais; Francesca Marino-Merlo; Jocelyn Turpin; Charles R Bangham; Olivier Hermine; Antonio Mastino; Ali Bazarbachi
Journal:  Blood Adv       Date:  2017-05-05

5.  HTLV-1 myelopathy after renal transplant and antiviral prophylaxis: the need for screening.

Authors:  David Moreno-Ajona; José Ramón Yuste; Paloma Martín; Jaime Gállego Pérez-Larraya
Journal:  J Neurovirol       Date:  2018-03-12       Impact factor: 2.643

6.  Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?

Authors:  Marie-Olivia Chandesris; David Ghez; Caroline Besson; Felipe Suarez; Richard Delarue; Marie-Thérèse Rubio; Ali Bazarbachi; Bruno Varet; Olivier Hermine
Journal:  BMJ Case Rep       Date:  2009-08-10

7.  Opposing effects of a tyrosine-based sorting motif and a PDZ-binding motif regulate human T-lymphotropic virus type 1 envelope trafficking.

Authors:  Anna Ilinskaya; Gisela Heidecker; David Derse
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

8.  Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro.

Authors:  Upal Roy; Scott A Simpson; Debasis Mondal; Sandra Eloby-Childress; Elsa L Winsor; Mark A Beilke
Journal:  J Med Virol       Date:  2008-03       Impact factor: 2.327

9.  Effect of phosphonated carbocyclic 2'-oxa-3'-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro.

Authors:  Emanuela Balestrieri; Claudia Matteucci; Arianna Ascolani; Anna Piperno; Roberto Romeo; Giovanni Romeo; Ugo Chiacchio; Antonio Mastino; Beatrice Macchi
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

10.  Human T-cell lymphotropic virus type 1 exposures following blood-borne virus incidents in central Australia, 2002-2012.

Authors:  S Hewagama; S Krishnaswamy; L King; J Davis; R Baird
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.